Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 서민석 | - |
dc.date.accessioned | 2018-11-22T06:11:18Z | - |
dc.date.available | 2018-11-22T06:11:18Z | - |
dc.date.issued | 2016-09 | - |
dc.identifier.citation | Journal of Commercial Biotechnology, v. 22, NO. 2, Page. 6-18 | en_US |
dc.identifier.issn | 1462-8732 | - |
dc.identifier.issn | 1478-565x | - |
dc.identifier.uri | https://commercialbiotechnology.com/index.php/jcb/article/view/736 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/80579 | - |
dc.description.abstract | In the pharmaceutical industry, companies are currently facing great challenges in developing new products due to patent expiration and decreasing profitability. In particular, the decrease in R&D productivity caused by the constant increase in the development period and cost of innovative new drugs means that the expectations of investors cannot be met. This study examined the successful case of Royalty Pharma's business model, which adopted securitization, a new investment method that makes advance payments of future profits in order to overcome the decline in R&D productivity and enables the pharmaceutical manufacturers (as patent owners) to resolve the issue of attracting investment funds, while also making these funds available for other development projects. It examined the role in the biopharmaceutical sector of patent aggregating companies in providing the competency to analyze patent technologies and to create investment megafunds, as well as the success factors that can lead to a virtuous cycle of product development. From this analysis, the application of a patentbased business model is proposed for small and mid-sized pharmaceutical industries. | en_US |
dc.language.iso | en | en_US |
dc.publisher | thinkBiotech | en_US |
dc.subject | royalty pharma | en_US |
dc.subject | translational research | en_US |
dc.subject | patent aggregation | en_US |
dc.subject | patent broker | en_US |
dc.title | Intellectual property business models using patent acquisition: A case study of Royalty Pharma Inc. | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 22 | - |
dc.identifier.doi | 10.5912/jcb736 | - |
dc.relation.page | 6-18 | - |
dc.relation.journal | Journal of Commercial Biotechnology | - |
dc.contributor.googleauthor | Lim, Su Young | - |
dc.contributor.googleauthor | Suh, Minsuk | - |
dc.relation.code | 2016031214 | - |
dc.sector.campus | S | - |
dc.sector.daehak | GRADUATE SCHOOL OF TECHNOLOGY & INNOVATION MANAGEMENT[S] | - |
dc.sector.department | DEPARTMENT OF TECHNOLOGY MANAGEMENT | - |
dc.identifier.pid | mssuh | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.